Aytu BioPharma, Inc. stock is down -20.55% since 30 days ago. The next earnings date is Feb 20, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 28.57% of the previous 6 December’s closed higher than November.
Aytu Biopharma, Inc. focuses on developing and commercializing novel therapeutics and consumer healthcare products. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the. treatment of seasonal and perennial allergies.